Clinical Trial Detail

NCT ID NCT04125719
Title PVSRIPO in Combination With Nivolumab in Melanoma (PPD1)
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Darell D. Bigner, MD, PhD
Indications

melanoma

Therapies

Nivolumab + PVSRIPO

Age Groups: adult senior

No variant requirements are available.